Full-Time

Associate Software Engineer

Posted on 10/1/2025

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Category
Software Engineering (2)
,
Required Skills
Kubernetes
Python
JavaScript
NoSQL
Tensorflow
Pytorch
SQL
Java
Docker
Elasticsearch
Databricks
Google Cloud Platform
Requirements
  • Master’s degree in computer science and engineering preferred with 2-4 years of software development experience OR Bachelor’s degree in computer science and engineering preferred with 2-5 years of software development experience
  • 1–3 years of experience building AI/ML models, ideally in search, NLP, or biomedical domains
  • Proficiency in Python and frameworks such as PyTorch, TensorFlow, Hugging Face Transformers
  • Experience with search technologies like Elasticsearch, OpenSearch, or vector search tools
  • Solid understanding of NLP techniques: embeddings, transformers, entity recognition, text classification
  • Hands on experience with various AI models, Google Cloud Platform Search Engines, Google Cloud Platform cloud services
  • Proficient in programming language AI/ML, Python, Java Crawlers, JavaScript, SQL/NoSQL, Databricks/RDS, Data engineering, S3 Buckets, DynamoDB
  • Strong problem solving, analytical skills; Ability to learn quickly; Excellent communication and interpersonal skills
Responsibilities
  • Design and implement search algorithms using NLP, machine learning, semantic understanding, and deep learning models
  • Build and fine-tune models for information retrieval, query expansion, document ranking, summarization, and Q&A systems
  • Support integration of LLMs (e.g., GPT, BERT, BioBERT) for semantic and generative search
  • Train and evaluate custom models for biomedical named entity recognition, relevance ranking, and similarity search
  • Build and deploy vector-based search systems using embeddings and vector databases
  • Work closely with platform engineers to integrate AI models into scalable cloud-based infrastructures (AWS, Azure, GCP)
  • Package and deploy search services using containerization (Docker, Kubernetes) and modern MLOps pipelines
  • Preprocess and structure unstructured content such as clinical trial reports, research articles, and regulatory documents
  • Apply knowledge graphs, taxonomies, and ontologies (e.g., MeSH, UMLS, SNOMED) to enhance search results
  • Build and deploy recommendation systems models, utilize AIML infrastructure, and contribute to model optimization and data processing
  • Experience in Generative AI on Search Engines
  • Experience in integrating Generative AI capabilities and Vision Models to enrich content quality and user engagement
  • Generative AI tasks such as content summarization, deduping and metadata quality
  • Implement KPI measurement frameworks to evaluate the quality and performance of delivered models, including those utilizing Generative AI
  • Developing and maintaining Deep Learning models for data quality checks, visual similarity scoring, and content tagging
  • Continually researching current and emerging technologies and proposing changes where needed
  • Implement GenAI solutions, utilize ML infrastructure, and contribute to data preparation, optimization, and performance enhancements
Desired Qualifications
  • Experience in AI/ML, Java, Python
  • Experienced with Fast Python APIs, GraphQL
  • Experience with design patterns, data structures, data modelling, data algorithms
  • Experienced with AWS/Azure Platform, Building and deploying the code
  • Experience in PostgreSQL SQL / MongoDB SQL database, vector database for large language models, Databricks or RDS, S3 Buckets
  • Knowledge of LLMs, generative AI, and their use in enterprise search
  • Experience in Google Cloud Search and Google Cloud Storage
  • Experience with popular large language models
  • Experience with Langchain or llamaIndex framework for language models
  • Experience with prompt engineering, model fine tuning
  • Knowledge of NLP techniques for text analysis and sentiment analysis
  • Experience in Agile software development methodologies
  • End to End testing as part of Test Driven Development
  • Willingness to work on Full stack Applications
  • Exposure to MLOps tools like MLflow, Airflow, or SageMaker
  • Excellent analytical and troubleshooting skills
  • Strong verbal and written communication skills
  • Ability to work effectively with global, remote teams
  • High degree of initiative and self-motivation
  • Ability to manage multiple priorities successfully
  • Team-oriented, with a focus on achieving team goals
  • Strong presentation and public speaking skills

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Tarlatamab wins China NMPA approval May 2026 for $2B+ sales potential.
  • Q1 2026 revenues hit $8.6B with 16 brands posting double-digit growth.
  • Zai Lab partners on DLL3-ADC plus IMDELLTRA for SCLC trials.

What critics are saying

  • Prolia sales drop 34% to $727M from biosimilar competition in Q1 2026.
  • FDA warns Tavneos causes liver injuries, proposes approval withdrawal.
  • Horizon drugs Tepezza, Uplizna, Krystexxa underperform 19 months post-acquisition.

What makes Amgen unique

  • Amgen's BiTE platform establishes IMDELLTRA as second-line SCLC standard.
  • MariTide advances in Phase III obesity trials with monthly dosing.
  • UPLIZNA surges 73% post-IgG4 and gMG approvals in 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.

INACTIVE